Company continues to advance an innovative pipeline of NKT cell regulators for the treatment of high-value inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, Sept. 30, 2024 (GLOBE NEWSWIRE) ...
Company’s lead program, GRI-0621, has demonstrated ability to inhibit the activity of type I invariant NKT (iNKT) cells early in the inflammatory cascade to prevent cytokine release, cellular ...
“We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for Translational Medicine. “And TNF-α is still the most contested—and the most ...
Agonists of immune checkpoint modulators for treating autoimmune and inflammatory disorders have shown high potential in immunotherapy. P-selectin glycoprotein ligand 1 (PSGL-1) is known to exert ...
GRI Bio, Inc., a biotechnology company focused on developing Natural Killer T cell modulators for inflammatory, fibrotic, and autoimmune diseases, announced that it has regained compliance with Nasdaq ...
UCB SA has identified imidazotriazine derivatives acting as interleukin-17 (IL-17) modulators reported to be useful for the treatment of inflammation and autoimmune diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results